BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xiao MW, Lin SX, Shen ZH, Luo WW, Wang XY. Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract 2019;2019:1484598. [PMID: 31885541 DOI: 10.1155/2019/1484598] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Rosqvist F, Rydell A, Iggman D. The Effects of Foods on Blood Lipids in Non-alcoholic Fatty Liver Disease (NAFLD)-A Systematic Review and Meta-Analysis. Front Nutr 2020;7:613221. [PMID: 33392241 DOI: 10.3389/fnut.2020.613221] [Reference Citation Analysis]
2 Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res 2021;7:11. [PMID: 33490737 DOI: 10.20517/2394-5079.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chen J, Vitetta L. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. Int J Mol Sci 2020;21:E5214. [PMID: 32717871 DOI: 10.3390/ijms21155214] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
4 Fougerat A, Montagner A, Loiseau N, Guillou H, Wahli W. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. Cells 2020;9:E1638. [PMID: 32650421 DOI: 10.3390/cells9071638] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
5 Barone M, D'Amico F, Fabbrini M, Rampelli S, Brigidi P, Turroni S. Over-feeding the gut microbiome: A scoping review on health implications and therapeutic perspectives. World J Gastroenterol 2021; 27(41): 7041-7064 [PMID: 34887627 DOI: 10.3748/wjg.v27.i41.7041] [Reference Citation Analysis]
6 Michels N, Zouiouich S, Vanderbauwhede B, Vanacker J, Indave Ruiz BI, Huybrechts I. Human microbiome and metabolic health: An overview of systematic reviews. Obes Rev 2022;:e13409. [PMID: 34978141 DOI: 10.1111/obr.13409] [Reference Citation Analysis]
7 Sumida Y, Yoneda M, Toyoda H, Yasuda S, Tada T, Hayashi H, Nishigaki Y, Suzuki Y, Naiki T, Morishita A, Tobita H, Sato S, Kawabe N, Fukunishi S, Ikegami T, Kessoku T, Ogawa Y, Honda Y, Nakahara T, Munekage K, Ochi T, Sawada K, Takahashi A, Arai T, Kogiso T, Kimoto S, Tomita K, Notsumata K, Nonaka M, Kawata K, Takami T, Kumada T, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone? Int J Mol Sci 2020;21:E4939. [PMID: 32668632 DOI: 10.3390/ijms21144939] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Park EJ, Lee YS, Kim SM, Park GS, Lee YH, Jeong DY, Kang J, Lee HJ. Beneficial Effects of Lactobacillus plantarum Strains on Non-Alcoholic Fatty Liver Disease in High Fat/High Fructose Diet-Fed Rats. Nutrients 2020;12:E542. [PMID: 32093158 DOI: 10.3390/nu12020542] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
9 Shirvani-Rad S, Tabatabaei-Malazy O, Mohseni S, Hasani-Ranjbar S, Soroush AR, Hoseini-Tavassol Z, Ejtahed HS, Larijani B. Probiotics as a Complementary Therapy for Management of Obesity: A Systematic Review. Evid Based Complement Alternat Med 2021;2021:6688450. [PMID: 33552218 DOI: 10.1155/2021/6688450] [Reference Citation Analysis]
10 Yang R, Shang J, Zhou Y, Liu W, Tian Y, Shang H. Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 2021;15:1401-9. [PMID: 34877910 DOI: 10.1080/17474124.2022.2016391] [Reference Citation Analysis]
11 Coleman MJ, Espino LM, Lebensohn H, Zimkute MV, Yaghooti N, Ling CL, Gross JM, Listwan N, Cano S, Garcia V, Lovato DM, Tigert SL, Jones DR, Gullapalli RR, Rakov NE, Torrazza Perez EG, Castillo EF. Individuals with Metabolic Syndrome Show Altered Fecal Lipidomic Profiles with No Signs of Intestinal Inflammation or Increased Intestinal Permeability. Metabolites 2022;12:431. [DOI: 10.3390/metabo12050431] [Reference Citation Analysis]
12 Hartmann P, Schnabl B. New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2021;41:87-102. [PMID: 33957682 DOI: 10.1055/s-0040-1719174] [Reference Citation Analysis]
13 Gawlik-Kotelnicka O, Strzelecki D. Probiotics as a Treatment for "Metabolic Depression"? A Rationale for Future Studies. Pharmaceuticals (Basel) 2021;14:384. [PMID: 33924064 DOI: 10.3390/ph14040384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Ren TY, Li XY, Fan JG. Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try. Clin Mol Hepatol 2021;27:83-6. [PMID: 33317240 DOI: 10.3350/cmh.2020.0298] [Reference Citation Analysis]